PDUFA date set for idelalisib in lymphoma

Share this article:

Gilead's idelalisib got the all-clear for breakthrough designation for chronic lymphocytic leukemia (CLL), but the FDA is treating the drug like any other therapy when it comes to refractory indolent non-Hodgkin's lymphoma (NHL). BioCentury reports that the FDA set aside September 11 as the PDUFA date for this latter indication.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.